{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T06:57:28Z","timestamp":1758265048089,"version":"3.37.3"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004595","name":"Universiti Sains Malaysia","doi-asserted-by":"publisher","award":["Bridging Grant (Grant No:304.PFARMASI.6316196)"],"award-info":[{"award-number":["Bridging Grant (Grant No:304.PFARMASI.6316196)"]}],"id":[{"id":"10.13039\/501100004595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s10928-022-09833-9","type":"journal-article","created":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T19:06:49Z","timestamp":1668539209000},"page":"21-31","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Pharmacometric modeling of drug adverse effects: an application of mixture models in schizophrenia spectrum disorder patients treated with clozapine"],"prefix":"10.1007","volume":"50","author":[{"given":"Orwa","family":"Albitar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siti Maisharah Sheikh","family":"Ghadzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabariah Noor","family":"Harun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siti Nor Aizah","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria C.","family":"Kjellsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,15]]},"reference":[{"key":"9833_CR1","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.3390\/PHARMACEUTICS13081121","volume":"13","author":"O Albitar","year":"2021","unstructured":"Albitar O, Harun SN, Ahmad SNA, Ghadzi SMS (2021) A repeated time-to-positive symptoms improvement among Malaysian patients with schizophrenia spectrum disorders treated with clozapine. Pharmaceutics 13:1121. https:\/\/doi.org\/10.3390\/PHARMACEUTICS13081121","journal-title":"Pharmaceutics"},{"key":"9833_CR2","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","volume":"174","author":"OD Howes","year":"2017","unstructured":"Howes OD, McCutcheon R, Agid O et al (2017) Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology. Am J Psychiatry 174:216\u2013229. https:\/\/doi.org\/10.1176\/appi.ajp.2016.16050503","journal-title":"Am J Psychiatry"},{"key":"9833_CR3","doi-asserted-by":"publisher","first-page":"e0243437","DOI":"10.1371\/journal.pone.0243437","volume":"15","author":"E Iqbal","year":"2020","unstructured":"Iqbal E, Govind R, Romero A et al (2020) The side effect profile of Clozapine in real world data of three large mental health hospitals. PLoS ONE 15:e0243437. https:\/\/doi.org\/10.1371\/journal.pone.0243437","journal-title":"PLoS ONE"},{"key":"9833_CR4","doi-asserted-by":"publisher","first-page":"113698","DOI":"10.1016\/j.psychres.2020.113698","volume":"297","author":"F Martini","year":"2021","unstructured":"Martini F, Spangaro M, Buonocore M et al (2021) Clozapine tolerability in treatment resistant schizophrenia: exploring the role of sex. Psychiatry Res 297:113698. https:\/\/doi.org\/10.1016\/j.psychres.2020.113698","journal-title":"Psychiatry Res"},{"key":"9833_CR5","first-page":"1","volume-title":"Basic and clinical pharmacology","author":"BG Katzung","year":"2017","unstructured":"Katzung BG (2017) Introduction: The Nature of Drugs & Drug Development & Regulation. In: Katzung BG (ed) Basic and clinical pharmacology, 14th edn. McGraw-Hill, New York, pp 1\u201319","edition":"14"},{"key":"9833_CR6","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s00228-016-2030-4","volume":"72","author":"AHM de Vries Schultink","year":"2016","unstructured":"de Vries Schultink AHM, Suleiman AA, Schellens JHM et al (2016) Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment. Eur J Clin Pharmacol 72:645\u2013653","journal-title":"Eur J Clin Pharmacol"},{"key":"9833_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1111\/bcp.12749","volume":"81","author":"EJ Phillips","year":"2016","unstructured":"Phillips EJ (2016) Classifying ADRs\u2014does dose matter? Br J Clin Pharmacol 81:10\u201312","journal-title":"Br J Clin Pharmacol"},{"key":"9833_CR8","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1136\/bmj.327.7425.1222","volume":"327","author":"JK Aronson","year":"2003","unstructured":"Aronson JK, Ferner RE (2003) Joining the DoTS: new approach to classifying adverse drug reactions. Br Med J 327:1222\u20131225","journal-title":"Br Med J"},{"key":"9833_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/bcp.12170","volume":"79","author":"N Holford","year":"2015","unstructured":"Holford N (2015) Clinical pharmacology = disease progression + drug action. Br J Clin Pharmacol 79:18\u201327. https:\/\/doi.org\/10.1111\/bcp.12170","journal-title":"Br J Clin Pharmacol"},{"key":"9833_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.12793\/tcp.2019.27.4.123","volume":"27","author":"N Holford","year":"2019","unstructured":"Holford N (2019) Treatment response and disease progression. Transl Clin Pharmacol 27:123\u2013126. https:\/\/doi.org\/10.12793\/tcp.2019.27.4.123","journal-title":"Transl Clin Pharmacol"},{"key":"9833_CR11","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1208\/s12248-009-9093-4","volume":"11","author":"KC Carlsson","year":"2009","unstructured":"Carlsson KC, Savi RM, Hooker AC, Karlsson MO (2009) Modeling subpopulations with the $MIXTURE subroutine in NONMEM: finding the individual probability of belonging to a subpopulation for the use in model analysis and improved decision making. AAPS J 11:148\u2013154. https:\/\/doi.org\/10.1208\/s12248-009-9093-4","journal-title":"AAPS J"},{"key":"9833_CR12","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/J.PMRJ.2015.07.011","volume":"7","author":"KL Sainani","year":"2015","unstructured":"Sainani KL (2015) Dealing with missing data. PM&R 7:990\u2013994. https:\/\/doi.org\/10.1016\/J.PMRJ.2015.07.011","journal-title":"PM&R"},{"key":"9833_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1002\/psp4.12374","volume":"8","author":"Y Wang","year":"2019","unstructured":"Wang Y, Liu X (2019) Handling missing dosing history in population pharmacokinetic modeling: an extension to MDM method. CPT Pharmacomet Syst Pharmacol 8:39\u201349. https:\/\/doi.org\/10.1002\/psp4.12374","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"9833_CR14","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1177\/0091270010362536","volume":"51","author":"PM Jauslin","year":"2011","unstructured":"Jauslin PM, Frey N, Karlsson MO (2011) Modeling of 24-hour glucose and insulin profiles of patients with type 2 diabetes. J Clin Pharmacol 51:153\u2013164. https:\/\/doi.org\/10.1177\/0091270010362536","journal-title":"J Clin Pharmacol"},{"key":"9833_CR15","doi-asserted-by":"publisher","first-page":"429","DOI":"10.2165\/11590590-000000000-00000","volume":"50","author":"V Pilla Reddy","year":"2011","unstructured":"Pilla Reddy V, Kozielska M, Johnson M et al (2011) Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders. Clin Pharmacokinet 50:429\u2013450","journal-title":"Clin Pharmacokinet"},{"key":"9833_CR16","volume-title":"NONMEM users guides (1989\u20132008)","author":"SL Beal","year":"2008","unstructured":"Beal SL, Shiener LB, Boeckman AJ (2008) NONMEM users guides (1989\u20132008). Icon Development Solutions, Ellicott City"},{"key":"9833_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO (2011) Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 13:143\u2013151. https:\/\/doi.org\/10.1208\/s12248-011-9255-z","journal-title":"AAPS J"},{"key":"9833_CR18","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s10928-019-09632-9","volume":"46","author":"U Arshad","year":"2019","unstructured":"Arshad U, Chasseloup E, Nordgren R, Karlsson MO (2019) Development of visual predictive checks accounting for multimodal parameter distributions in mixture models. J Pharmacokinet Pharmacodyn 46:241\u2013250. https:\/\/doi.org\/10.1007\/s10928-019-09632-9","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9833_CR19","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s10928-016-9487-8","volume":"43","author":"AG Dosne","year":"2016","unstructured":"Dosne AG, Bergstrand M, Harling K, Karlsson MO (2016) Improving the estimation of parameter uncertainty distributions in nonlinear mixed effects models using sampling importance resampling. J Pharmacokinet Pharmacodyn 43:583\u2013596. https:\/\/doi.org\/10.1007\/s10928-016-9487-8","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9833_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/PSP.2013.24@10.1002\/(ISSN)2163-8306(CAT)VIRTUALISSUES(VI)TUTORIALS","volume":"2","author":"R Keizer","year":"2013","unstructured":"Keizer R, Karlsson M, Hooker A (2013) Modeling and simulation workbench for NONMEM: tutorial on Pirana, PsN, and Xpose. CPT Pharmacomet Syst Pharmacol 2:1\u20139. https:\/\/doi.org\/10.1038\/PSP.2013.24@10.1002\/(ISSN)2163-8306(CAT)VIRTUALISSUES(VI)TUTORIALS","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"9833_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0169-2607(98)00067-4","volume":"58","author":"EN Jonsson","year":"1998","unstructured":"Jonsson EN, Karlsson MO (1998) Xpose - An S-PLUS based population pharmacokinetic\/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 58:51\u201364. https:\/\/doi.org\/10.1016\/S0169-2607(98)00067-4","journal-title":"Comput Methods Programs Biomed"},{"key":"9833_CR22","unstructured":"Hooker AC, Karlsson MO, Wilkins JJ, Jonsson EN (2014) xpose4: tools for nonlinear mixed-effect model building and diagnostics. R package version 4.6.1. http:\/\/xpose.sourceforge.net. Accessed 17 Feb 2020"},{"key":"9833_CR23","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/sj.clpt.6100228","volume":"82","author":"DR Mould","year":"2007","unstructured":"Mould DR, Denman NG, Duffull S (2007) Using disease progression models as a tool to detect drug effect. Clin Pharmacol Ther 82:81\u201386","journal-title":"Clin Pharmacol Ther"},{"key":"9833_CR24","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/MDS.26644","volume":"31","author":"CS Venuto","year":"2016","unstructured":"Venuto CS, Potter NB, Dorsey ER, Kieburtz K (2016) A review of disease progression models of Parkinson\u2019s disease and applications in clinical trials. Mov Disord 31:947\u2013956. https:\/\/doi.org\/10.1002\/MDS.26644","journal-title":"Mov Disord"},{"key":"9833_CR25","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1365-2125.2012.04308.x","volume":"75","author":"MN Samtani","year":"2013","unstructured":"Samtani MN, Raghavan N, Shi Y et al (2013) Disease progression model in subjects with mild cognitive impairment from the Alzheimer\u2019s disease neuroimaging initiative: CSF biomarkers predict population subtypes. Br J Clin Pharmacol 75:146\u2013161. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04308.x","journal-title":"Br J Clin Pharmacol"},{"key":"9833_CR26","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1002\/JCPH.399","volume":"55","author":"C Passey","year":"2015","unstructured":"Passey C, Kimko H, Nandy P, Kagan L (2015) Osteoarthritis disease progression model using six year follow-up data from the osteoarthritis initiative. J Clin Pharmacol 55:269\u2013278. https:\/\/doi.org\/10.1002\/JCPH.399","journal-title":"J Clin Pharmacol"},{"key":"9833_CR27","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/1753-6405.12804","volume":"42","author":"R Wilson","year":"2018","unstructured":"Wilson R, Abbott JH (2018) Age, period and cohort effects on body mass index in New Zealand, 1997\u20132038. Aust N Z J Public Health 42:396\u2013402. https:\/\/doi.org\/10.1111\/1753-6405.12804","journal-title":"Aust N Z J Public Health"},{"key":"9833_CR28","doi-asserted-by":"publisher","DOI":"10.1073\/PNAS.2020167118\/-\/DCSUPPLEMENTAL","author":"YC Yang","year":"2021","unstructured":"Yang YC, Walsh CE, Johnson MP et al (2021) Life-course trajectories of body mass index from adolescence to old age: racial and educational disparities. Proc Natl Acad Sci USA. https:\/\/doi.org\/10.1073\/PNAS.2020167118\/-\/DCSUPPLEMENTAL","journal-title":"Proc Natl Acad Sci USA"},{"key":"9833_CR29","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1023\/A:1016181505556","volume":"19","author":"T Shiiki","year":"2002","unstructured":"Shiiki T, Hashimoto Y, Inui KI (2002) Simulation for population pharmacodynamic analysis of dose-ranging trials: usefulness of the mixture model analysis for detecting nonresponders. Pharm Res 19:909\u2013913. https:\/\/doi.org\/10.1023\/A:1016181505556","journal-title":"Pharm Res"},{"key":"9833_CR30","doi-asserted-by":"crossref","unstructured":"Subramanian S, V\u00f6llm BA, Huband N (2017) Clozapine dose for schizophrenia. Cochrane Database Syst Rev\u00a02017","DOI":"10.1002\/14651858.CD009555.pub2"},{"key":"9833_CR31","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1023\/B:JOPA.0000008157.26321.3C","volume":"30","author":"KG Kowalski","year":"2003","unstructured":"Kowalski KG, McFadyen L, Hutmacher MM et al (2003) A two-part mixture model for longitudinal adverse event severity data. J Pharmacokinet Pharmacodyn 30:315\u2013336. https:\/\/doi.org\/10.1023\/B:JOPA.0000008157.26321.3C","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"9833_CR32","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1093\/oxfordjournals.schbul.a033333","volume":"24","author":"CR Young","year":"1998","unstructured":"Young CR, Bowers MB, Mazure CM (1998) Management of the adverse effects of clozapine. Schizophr Bull 24:381\u2013390. https:\/\/doi.org\/10.1093\/oxfordjournals.schbul.a033333","journal-title":"Schizophr Bull"},{"key":"9833_CR33","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2174\/157488631002150515120209","volume":"10","author":"N Hyde","year":"2015","unstructured":"Hyde N, Dodd S, Venugopal K et al (2015) Prevalence of cardiovascular and metabolic events in patients prescribed clozapine: a retrospective observational, clinical cohort study. Curr Drug Saf 10:125\u2013131. https:\/\/doi.org\/10.2174\/157488631002150515120209","journal-title":"Curr Drug Saf"},{"key":"9833_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.EURPSY.2013.08.001","volume":"29","author":"C Schneider","year":"2014","unstructured":"Schneider C, Corrigall R, Hayes D et al (2014) Systematic review of the efficacy and tolerability of Clozapine in the treatment of youth with early onset schizophrenia. Eur Psychiatry 29:1\u201310. https:\/\/doi.org\/10.1016\/J.EURPSY.2013.08.001","journal-title":"Eur Psychiatry"},{"key":"9833_CR35","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1177\/1039856216665282","volume":"25","author":"G Tso","year":"2017","unstructured":"Tso G, Kumar P, Jayasooriya T et al (2017) Metabolic monitoring and management among clozapine users. Aust Psychiatry 25:48\u201352. https:\/\/doi.org\/10.1177\/1039856216665282","journal-title":"Aust Psychiatry"},{"key":"9833_CR36","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.euroneuro.2015.12.035","volume":"26","author":"F Gressier","year":"2016","unstructured":"Gressier F, Porcelli S, Calati R, Serretti A (2016) Pharmacogenetics of clozapine response and induced weight gain: a comprehensive review and meta-analysis. Eur Neuropsychopharmacol 26:163\u2013185","journal-title":"Eur Neuropsychopharmacol"},{"key":"9833_CR37","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/JCP.0000000000000476","volume":"36","author":"SL Lau","year":"2016","unstructured":"Lau SL, Muir C, Assur Y et al (2016) Predicting weight gain in patients treated with clozapine: the role of sex, body mass index, and smoking. J Clin Psychopharmacol 36:120\u2013124. https:\/\/doi.org\/10.1097\/JCP.0000000000000476","journal-title":"J Clin Psychopharmacol"},{"key":"9833_CR38","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.schres.2008.10.023","volume":"108","author":"YM Bai","year":"2009","unstructured":"Bai YM, Chen JY, Chen TT et al (2009) Weight gain with clozapine: 8-year cohort naturalistic study among hospitalized Chinese schizophrenia patients. Schizophr Res 108:122\u2013126. https:\/\/doi.org\/10.1016\/j.schres.2008.10.023","journal-title":"Schizophr Res"},{"key":"9833_CR39","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1176\/appi.ajp.157.6.975","volume":"157","author":"DC Henderson","year":"2000","unstructured":"Henderson DC, Cagliero E, Gray C et al (2000) Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 157:975\u2013981. https:\/\/doi.org\/10.1176\/appi.ajp.157.6.975","journal-title":"Am J Psychiatry"},{"key":"9833_CR40","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.4088\/JCP.08r04392","volume":"70","author":"V Simon","year":"2009","unstructured":"Simon V, Van Winkel R, De Hert M (2009) Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry 70:1041\u20131050. https:\/\/doi.org\/10.4088\/JCP.08r04392","journal-title":"J Clin Psychiatry"},{"key":"9833_CR41","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1097\/JCP.0000000000000926","volume":"38","author":"FJ Diaz","year":"2018","unstructured":"Diaz FJ, Josiassen RC, de Leon J (2018) The Effect of body weight changes on total plasma clozapine concentrations determined by applying a statistical model to the data from a double-blind trial. J Clin Psychopharmacol 38:442\u2013446. https:\/\/doi.org\/10.1097\/JCP.0000000000000926","journal-title":"J Clin Psychopharmacol"},{"key":"9833_CR42","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/0269881120985166","volume":"35","author":"M Kuzin","year":"2021","unstructured":"Kuzin M, Haen E, Hiemke C et al (2021) Body mass index as a determinant of clozapine plasma concentrations: a pharmacokinetic-based hypothesis. J Psychopharmacol 35:273\u2013278. https:\/\/doi.org\/10.1177\/0269881120985166","journal-title":"J Psychopharmacol"},{"key":"9833_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2458-13-797\/FIGURES\/3","volume":"13","author":"C Ranasinghe","year":"2013","unstructured":"Ranasinghe C, Gamage P, Katulanda P et al (2013) Relationship between body mass index (BMI) and body fat percentage, estimated by bioelectrical impedance, in a group of Sri Lankan adults: a cross sectional study. BMC Public Health 13:1\u20138. https:\/\/doi.org\/10.1186\/1471-2458-13-797\/FIGURES\/3","journal-title":"BMC Public Health"},{"key":"9833_CR44","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1093\/AJCN\/72.5.1074","volume":"72","author":"RJ Kuczmarski","year":"2000","unstructured":"Kuczmarski RJ, Flegal KM (2000) Criteria for definition of overweight in transition: background and recommendations for the United States. Am J Clin Nutr 72:1074\u20131081. https:\/\/doi.org\/10.1093\/AJCN\/72.5.1074","journal-title":"Am J Clin Nutr"},{"key":"9833_CR45","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1017\/S0033291719000369","volume":"50","author":"XH Li","year":"2020","unstructured":"Li XH, Zhong XM, Lu L et al (2020) The prevalence of agranulocytosis and related death in clozapine-treated patients: a comprehensive meta-analysis of observational studies. Psychol Med 50:583\u2013594. https:\/\/doi.org\/10.1017\/S0033291719000369","journal-title":"Psychol Med"},{"key":"9833_CR46","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/ACPS.12898","volume":"138","author":"N Myles","year":"2018","unstructured":"Myles N, Myles H, Xia S et al (2018) Meta-analysis examining the epidemiology of clozapine-associated neutropenia. Acta Psychiatr Scand 138:101\u2013109. https:\/\/doi.org\/10.1111\/ACPS.12898","journal-title":"Acta Psychiatr Scand"},{"key":"9833_CR47","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/J.AJP.2019.03.002","volume":"41","author":"N Tunsirimas","year":"2019","unstructured":"Tunsirimas N, Pariwatcharakul P, Choovanichvong S, Ratta-apha W (2019) Clozapine-induced agranulocytosis and leukopenia: Incidence, associated factors, and rate of hematologic adverse-effects monitoring in psychiatric out-patient services in Thailand. Asian J Psychiatr 41:13\u201316. https:\/\/doi.org\/10.1016\/J.AJP.2019.03.002","journal-title":"Asian J Psychiatr"},{"key":"9833_CR48","doi-asserted-by":"publisher","DOI":"10.4324\/9781315825731","volume-title":"Psychologists\u2019 psychotropic drug reference","author":"LA Pagliaro","year":"2020","unstructured":"Pagliaro LA, Pagliaro AM (2020) Psychologists\u2019 psychotropic drug reference. Taylor & Francis, New York"},{"key":"9833_CR49","doi-asserted-by":"publisher","first-page":"714","DOI":"10.3389\/FPHAR.2021.658734","volume":"0","author":"IR Willcocks","year":"2021","unstructured":"Willcocks IR, Legge SE, Nalmpanti M et al (2021) Clozapine metabolism is associated with absolute neutrophil count in individuals with treatment-resistant schizophrenia. Front Pharmacol 0:714. https:\/\/doi.org\/10.3389\/FPHAR.2021.658734","journal-title":"Front Pharmacol"},{"key":"9833_CR50","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/S40263-017-0469-1","volume":"31","author":"RL Smith","year":"2017","unstructured":"Smith RL, Haslemo T, Andreassen OA et al (2017) Correlation between serum concentrations of N-desmethylclozapine and granulocyte levels in patients with schizophrenia: a retrospective observational study. CNS Drugs 31:991\u2013997. https:\/\/doi.org\/10.1007\/S40263-017-0469-1","journal-title":"CNS Drugs"},{"key":"9833_CR51","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1007\/S00213-020-05746-Y","volume":"238","author":"MSA Tan","year":"2021","unstructured":"Tan MSA, Honarparvar F, Falconer JR et al (2021) A systematic review and meta-analysis of the association between clozapine and norclozapine serum levels and peripheral adverse drug reactions. Psychopharmacology 238:615\u2013637. https:\/\/doi.org\/10.1007\/S00213-020-05746-Y","journal-title":"Psychopharmacology"},{"key":"9833_CR52","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1136\/PGMJ.2004.031161","volume":"81","author":"S Rajagopal","year":"2005","unstructured":"Rajagopal S (2005) Clozapine, agranulocytosis, and benign ethnic neutropenia. Postgrad Med J 81:545\u2013546. https:\/\/doi.org\/10.1136\/PGMJ.2004.031161","journal-title":"Postgrad Med J"},{"key":"9833_CR53","doi-asserted-by":"crossref","unstructured":"Lally J, Docherty MJ, Maccabe JH (2016) Pharmacological interventions for clozapine-induced sinus tachycardia. Cochrane Database Syst Rev\u00a02016","DOI":"10.1002\/14651858.CD011566.pub2"},{"key":"9833_CR54","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1097\/YIC.0000000000000169","volume":"32","author":"BM Nilsson","year":"2017","unstructured":"Nilsson BM, Edstr\u00f6m O, Lindstr\u00f6m L et al (2017) Tachycardia in patients treated with clozapine versus antipsychotic long-acting injections. Int Clin Psychopharmacol 32:219. https:\/\/doi.org\/10.1097\/YIC.0000000000000169","journal-title":"Int Clin Psychopharmacol"},{"key":"9833_CR55","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/J.SCHRES.2018.03.017","volume":"199","author":"BM Nilsson","year":"2018","unstructured":"Nilsson BM, Lindstr\u00f6m L, Mohsen I et al (2018) Persistent tachycardia in clozapine treated patients: a 24-hour ambulatory electrocardiogram study. Schizophr Res 199:403\u2013406. https:\/\/doi.org\/10.1016\/J.SCHRES.2018.03.017","journal-title":"Schizophr Res"},{"key":"9833_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/9872936","volume":"2020","author":"O Albitar","year":"2020","unstructured":"Albitar O, Harun SN, Zainal H et al (2020) Population pharmacokinetics of clozapine: a systematic review. Biomed Res Int 2020:1\u201310. https:\/\/doi.org\/10.1155\/2020\/9872936","journal-title":"Biomed Res Int"},{"key":"9833_CR57","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.jpsychires.2008.11.001","volume":"43","author":"S Gebhardt","year":"2009","unstructured":"Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M et al (2009) Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course. J Psychiatr Res 43:620\u2013626. https:\/\/doi.org\/10.1016\/j.jpsychires.2008.11.001","journal-title":"J Psychiatr Res"},{"key":"9833_CR58","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3109\/08039488.2014.907340","volume":"68","author":"N Sepp\u00e4l\u00e4","year":"2014","unstructured":"Sepp\u00e4l\u00e4 N, Leinonen E, Viikki M, Kampman O (2014) Smoking and weight among patients using clozapine. Nord J Psychiatry 68:620\u2013625. https:\/\/doi.org\/10.3109\/08039488.2014.907340","journal-title":"Nord J Psychiatry"},{"key":"9833_CR59","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/sscp.202100068","volume":"5","author":"O Albitar","year":"2022","unstructured":"Albitar O, Murugaiyah V, Ibrahim B et al (2022) Clozapine and norclozapine monitoring in plasma following surfactant assisted dispersive liquid\u2013liquid microextraction. Sep Sci PLUS 5:1\u201310. https:\/\/doi.org\/10.1002\/sscp.202100068","journal-title":"Sep Sci PLUS"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-022-09833-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10928-022-09833-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-022-09833-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T14:02:56Z","timestamp":1676642576000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10928-022-09833-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,15]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["9833"],"URL":"https:\/\/doi.org\/10.1007\/s10928-022-09833-9","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"type":"print","value":"1567-567X"},{"type":"electronic","value":"1573-8744"}],"subject":[],"published":{"date-parts":[[2022,11,15]]},"assertion":[{"value":"24 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by the Medical Research and Ethics Committee, Ministry of Health, Malaysia (Research ID: NMRR-19-1297-46641).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}